(Total Views: 628)
Posted On: 07/14/2018 7:41:59 AM
Post# of 15624
Posted on the other board
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Develops Next Generation Cannabis based Orally Disintegrating Tablet
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has completed the development of orally disintegrating next generation cannabis-based Tablet. It is a substitute for the treatment using a smoking form of medical cannabis treatment.
The next generation tablet is developed using specific amounts of cannabidiol and cannabinoids tetrahydrocannabinol and cannabis extract. The various combinations of CBD and THC are used in this tablet to address different indications. The preclinical development of this drug is already completed. It is a fast acting and can be administered in controlled dosages.
The Chief Executive Officer of OWC Pharmaceutical Research Corp, Mordechai Bignitz said the development efforts of the company improves the quality lives of patients. The next generation cannabis-based drug is one of its efforts to improve the lives of patients.
OWC Pharmaceutical Research Corp Completes the Safety Study of Cannabis based Ointment
OWC Pharmaceutical Research Corp has completed the first part of the safety study of cannabis based ointment.
The ointment consists of medical grade cannabis for different disorders. The tolerability and safety of the ointment have been studied in medical volunteers. Director (Department of Dermatology), Professor Aviv Barzilai headed the safety study of the ointment. The medical volunteers have not suffered any adverse conditions during the study of the topical ointment.
The company will initiate the phase ii clinical study after completing the second part of the safety study. The ointment is developed for the treatment of psoriasis. It is also indicated for other skin diseases as well.
Mordechai Bignitz said the company is pleased to complete the clinical testing of this ointment. He further said the company is committed to develop and validate the cannabis based products to treat life threatening diseases and debilitating conditions.
The main aim of the company is to provide access to the cost effective and safe cannabis based products to the patients suffering from diseases like psoriasis.
Brief Information about OWC Pharmaceutical Research Corp
OWC Pharmaceutical Research Corp is engaged in medical R&D through One World Cannabis Ltd, its wholly owned subsidiary based in Israel. The company develops products using cannabis for the treatment of fibromyalgia, psoriasis, multiple myeloma, migraines, and PTSD.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Develops Next Generation Cannabis based Orally Disintegrating Tablet
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has completed the development of orally disintegrating next generation cannabis-based Tablet. It is a substitute for the treatment using a smoking form of medical cannabis treatment.
The next generation tablet is developed using specific amounts of cannabidiol and cannabinoids tetrahydrocannabinol and cannabis extract. The various combinations of CBD and THC are used in this tablet to address different indications. The preclinical development of this drug is already completed. It is a fast acting and can be administered in controlled dosages.
The Chief Executive Officer of OWC Pharmaceutical Research Corp, Mordechai Bignitz said the development efforts of the company improves the quality lives of patients. The next generation cannabis-based drug is one of its efforts to improve the lives of patients.
OWC Pharmaceutical Research Corp Completes the Safety Study of Cannabis based Ointment
OWC Pharmaceutical Research Corp has completed the first part of the safety study of cannabis based ointment.
The ointment consists of medical grade cannabis for different disorders. The tolerability and safety of the ointment have been studied in medical volunteers. Director (Department of Dermatology), Professor Aviv Barzilai headed the safety study of the ointment. The medical volunteers have not suffered any adverse conditions during the study of the topical ointment.
The company will initiate the phase ii clinical study after completing the second part of the safety study. The ointment is developed for the treatment of psoriasis. It is also indicated for other skin diseases as well.
Mordechai Bignitz said the company is pleased to complete the clinical testing of this ointment. He further said the company is committed to develop and validate the cannabis based products to treat life threatening diseases and debilitating conditions.
The main aim of the company is to provide access to the cost effective and safe cannabis based products to the patients suffering from diseases like psoriasis.
Brief Information about OWC Pharmaceutical Research Corp
OWC Pharmaceutical Research Corp is engaged in medical R&D through One World Cannabis Ltd, its wholly owned subsidiary based in Israel. The company develops products using cannabis for the treatment of fibromyalgia, psoriasis, multiple myeloma, migraines, and PTSD.
(0)
(0)
